In Q2 2026, Cormorant Asset Management held 48 positions worth $1.9B. They initiated 10 new positions and exited 71. Their largest holding was PRAX ($214.3M). Portfolio value shrank -1.3% versus the prior quarter.
Frequently asked questions
What stocks did Cormorant Asset Management own in Q2 2026?
Cormorant Asset Management held 48 biotech stocks in their 13F portfolio in Q2 2026. Their top positions include PRAX, BBIO, PBLS, RAPP, ERAS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Cormorant Asset Management's portfolio worth in Q2 2026?
Cormorant Asset Management's tracked biotech portfolio was worth $1.9B across 48 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
What did Cormorant Asset Management buy in Q2 2026?
Cormorant Asset Management initiated 10 new positions in Q2 2026, including PBLS, CLYM, DFTX, KLRA, IBIO and 5 more. They also increased 6 existing positions.
What did Cormorant Asset Management sell in Q2 2026?
Cormorant Asset Management fully exited 71 positions in Q2 2026, including KYTX, OMER, CGEM, IDYA, PRME and 66 more. They also trimmed 28 existing positions.
Is Cormorant Asset Management a biotech fund?
Healthcare-focused crossover fund that invests from late-stage private through public markets. Known for concentrated, high-conviction positions in clinical and commercial-stage biotech companies with strong scientific differentiation.
Want AI analysis, insider signals, and catalyst overlays for Cormorant Asset Management?
View latest Cormorant Asset Managementportfolio →